All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a comprehensive range of high-quality CART-related products and services aimed at targeting the B7-H4 protein in cancer therapy to speed up customers’ projects. Please find the appropriate products you desire.
The B7H4 protein is a member of the B7 family and plays a crucial role in tumor progression and immune evasion. Studies have shown that B7H4 is highly expressed in ovarian cancer, breast cancer, colorectal cancer, and pancreas cancer. Its expression in tumor cells is associated with increased proliferation, angiogenesis, tumor invasion, and metastasis, highlighting its significance as a target for cancer therapy.
Associated Disease
Creative Biolabs offers a range of advanced services for developing and testing Anti-B7H4 Chimeric Antigen Receptor T (CAR-T) cells. Our services include the design and construction of custom B7-H4 CAR, not only regular CAR constructs, but also various non-regular CAR constructs.
Fig.1 Schematic of Anti-B7H4 CAR constructs.1
The in vitro assays provided by Creative Biolabs enable the evaluation of B7-H4 CAR-T cells' functionality and specificity. We offer CAR expression testing to confirm the presence of B7H4 CAR on engineered T cells by various methods, such as FACS, WB, and qPCR.
Fig.2 B7H4 CAR (x-axis) expression of CAR-T cells after transduction of human T cells with the indicated CARs.1
The evaluation of cytokine release is a crucial component in assessing the efficacy and specificity of Anti-B7H4 CAR-T cells. Creative Biolabs offers various assays for detecting cytokine production by Anti-B7H4 CAR-T cells. These assays help provide insights into the immune response generated by the CAR-T cells upon encountering target cells expressing B7H4. By quantifying the levels of cytokines such as interferon-gamma (IFN-γ), interleukins, and tumor necrosis factor (TNF), researchers can ascertain the specificity and potency of the CAR-T therapy.
Fig.3 IFN-γ test of Anti-B7H4 CAR T cells co-cultured with B7H4(+) tumor cells.1
The in vitro cytotoxicity assay plays a crucial role in the evaluation and optimization of anti-B7H4 chimeric antigen receptor T (CAR-T) cell therapy. Creative Biolabs offers a range of advanced methods to assess the tumor-killing activity of anti-B7H4 CAR-T cells, such as flow cytometry cytotoxicity test, and real-time dynamic cytotoxicity analysis, providing valuable insights into the efficacy and specificity of the treatment.
Fig.4 In vitro cytotoxicity of anti-B7H4 CAR-T cells against different tumor cells at indicated E:T ratio.1
The success of Anti-B7H4 CAR-T cell therapy relies heavily on its efficacy in vivo, particularly in targeting cancerous cells expressing B7H4. Creative Biolabs offers comprehensive services for evaluating the effectiveness of Anti-B7H4 CAR-T cells through in vivo assays.
By employing approaches like bioluminescence imaging (BLI) and histological analysis, Creative Biolabs enables the monitoring and evaluation of the antitumor activities of Anti-B7H4 CAR-T cells in vivo. BLI allows for the visualization of tumor growth inhibition and provides insights into the dynamics of CAR-T cell-mediated tumor control.
Fig.5 In vivo efficacy of anti-B7H4 CAR-T cells in the OVCAR3-luc CDX models.1
Reference
CAT | Product Name | Host Cell Type | Target | scFv Clone | CAR Construction | CAR Cell Type | Inquiry & Datasheet |
CARJ-LX057 | Anti-B7H4 h(TM28-CD28-CD3ζ) CAR, Jurkat Cell | T lymphocyte | B7H4 | scFv-TM28-CD28-CD3ζ |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION